These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37908161)

  • 1. Editorial: Factors Driving New Variants of SARS-CoV-2, Immune Escape, and Resistance to Antiviral Treatments as the End of the COVID-19 Pandemic is Declared.
    Parums DV
    Med Sci Monit; 2023 Nov; 29():e942960. PubMed ID: 37908161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 Variants, Vaccines, and Host Immunity.
    Mistry P; Barmania F; Mellet J; Peta K; Strydom A; Viljoen IM; James W; Gordon S; Pepper MS
    Front Immunol; 2021; 12():809244. PubMed ID: 35046961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The COVID-19 Pandemic: SARS-CoV-2 Structure, Infection, Transmission, Symptomology, and Variants of Concern.
    Guest PC; Kesharwani P; Butler AE; Sahebkar A
    Adv Exp Med Biol; 2023; 1412():3-26. PubMed ID: 37378759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic Surveillance of SARS-CoV-2 M
    Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
    mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis.
    Liu Q; Qin C; Liu M; Liu J
    Infect Dis Poverty; 2021 Nov; 10(1):132. PubMed ID: 34776011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.
    Gong W; Parkkila S; Wu X; Aspatwar A
    Int Rev Immunol; 2023; 42(6):393-414. PubMed ID: 35635216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The World Health Organization COVID-19 surveillance database.
    Allan M; Lièvre M; Laurenson-Schafer H; de Barros S; Jinnai Y; Andrews S; Stricker T; Formigo JP; Schultz C; Perrocheau A; Fitzner J
    Int J Equity Health; 2022 Nov; 21(Suppl 3):167. PubMed ID: 36419127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.
    Anand U; Jakhmola S; Indari O; Jha HC; Chen ZS; Tripathi V; Pérez de la Lastra JM
    Front Immunol; 2021; 12():658519. PubMed ID: 34276652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the frequency and intensity of COVID-19 in patients with ankylosing spondylitis under anti-TNF therapy.
    Türk SM; Öztürk Z; Karataş D; Erkorkmaz Ü; Gönüllü E
    Turk J Med Sci; 2022 Apr; 52(2):522-523. PubMed ID: 36161620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune characterization and profiles of SARS-CoV-2 infected patients reveals potential host therapeutic targets and SARS-CoV-2 oncogenesis mechanism.
    Policard M; Jain S; Rego S; Dakshanamurthy S
    Virus Res; 2021 Aug; 301():198464. PubMed ID: 34058265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics.
    Kumar S; Çalışkan DM; Janowski J; Faist A; Conrad BCG; Lange J; Ludwig S; Brunotte L
    Front Immunol; 2021; 12():752227. PubMed ID: 34659259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Complementary Union of SARS-CoV2 Natural and Vaccine Induced Immune Responses.
    Torresi J; Edeling MA; Nolan T; Godfrey DI
    Front Immunol; 2022; 13():914167. PubMed ID: 35911696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group.
    Al-Shamsi HO; Alhazzani W; Alhuraiji A; Coomes EA; Chemaly RF; Almuhanna M; Wolff RA; Ibrahim NK; Chua MLK; Hotte SJ; Meyers BM; Elfiki T; Curigliano G; Eng C; Grothey A; Xie C
    Oncologist; 2020 Jun; 25(6):e936-e945. PubMed ID: 32243668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iota-Carrageenan Inhibits Replication of SARS-CoV-2 and the Respective Variants of Concern Alpha, Beta, Gamma and Delta.
    Fröba M; Große M; Setz C; Rauch P; Auth J; Spanaus L; Münch J; Ruetalo N; Schindler M; Morokutti-Kurz M; Graf P; Prieschl-Grassauer E; Grassauer A; Schubert U
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34947999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon resistance of emerging SARS-CoV-2 variants.
    Guo K; Barrett BS; Morrison JH; Mickens KL; Vladar EK; Hasenkrug KJ; Poeschla EM; Santiago ML
    Proc Natl Acad Sci U S A; 2022 Aug; 119(32):e2203760119. PubMed ID: 35867811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing SARS-CoV-2 variants among children and adolescents in Germany: relative risk of COVID-19-related hospitalization, ICU admission and mortality.
    Jank M; Oechsle AL; Armann J; Behrends U; Berner R; Chao CM; Diffloth N; Doenhardt M; Hansen G; Hufnagel M; Lander F; Liese JG; Muntau AC; Niehues T; von Both U; Verjans E; Weil K; von Kries R; Schroten H
    Infection; 2023 Oct; 51(5):1357-1367. PubMed ID: 36787015
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.